Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Rousselot

Showing results (81-90 of 195) with videos related to

Pageof 20
Sort By:
Oncotarget|May 12, 2016
Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuationJean Claude Chomel, Marie-Laure Bonnet, Nathalie Sorel, et al.
Cancer Immunology, Immunotherapy : CII|December 19, 2025
Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patientsEmilie Cayssials, Lucie Lefèvre, Amandine Decroos, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2013
Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisisDavid Ghez, Jean-Baptiste Micol, Florence Pasquier, et al.
Nature Communications|March 4, 2025
A metabolic synthetic lethality of phosphoinositide 3-kinase-driven cancerGuillaume P Andrieu, Mathieu Simonin, Aurélie Cabannes-Hamy, et al.
Biochemical Pharmacology|November 6, 2003
Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivoJérôme Larghero, Thibaut Leguay, Samia Mourah, et al.
Blood|August 23, 2003
Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phaseMartine Gardembas, Philippe Rousselot, Michel Tulliez, et al.
Haematologica|February 9, 2010
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinibNeil P Shah, Dong-Wook Kim, Hagop Kantarjian, et al.
Molecular Oncology|March 26, 2018
DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34<sup>+</sup> CD15<sup>-</sup> cells in early chronic-phase chronic myeloid leukemiaStéphanie Maupetit-Mehouas, Franck Court, Céline Bourgne, et al.
Seminars in Hematology|June 5, 2003
Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trialsFrançois Guilhot, Martine Gardembas, Philippe Rousselot, et al.
Blood|February 24, 2007
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trialHagop Kantarjian, Ricardo Pasquini, Nelson Hamerschlak, et al.
Pageof 20

Showing results (81-90 of 195) with videos related to

Sort By:
Pageof 20
Oncotarget|May 12, 2016
Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuationJean Claude Chomel, Marie-Laure Bonnet, Nathalie Sorel, et al.
Cancer Immunology, Immunotherapy : CII|December 19, 2025
Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patientsEmilie Cayssials, Lucie Lefèvre, Amandine Decroos, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2013
Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisisDavid Ghez, Jean-Baptiste Micol, Florence Pasquier, et al.
Nature Communications|March 4, 2025
A metabolic synthetic lethality of phosphoinositide 3-kinase-driven cancerGuillaume P Andrieu, Mathieu Simonin, Aurélie Cabannes-Hamy, et al.
Biochemical Pharmacology|November 6, 2003
Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivoJérôme Larghero, Thibaut Leguay, Samia Mourah, et al.
Blood|August 23, 2003
Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phaseMartine Gardembas, Philippe Rousselot, Michel Tulliez, et al.
Haematologica|February 9, 2010
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinibNeil P Shah, Dong-Wook Kim, Hagop Kantarjian, et al.
Molecular Oncology|March 26, 2018
DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34<sup>+</sup> CD15<sup>-</sup> cells in early chronic-phase chronic myeloid leukemiaStéphanie Maupetit-Mehouas, Franck Court, Céline Bourgne, et al.
Seminars in Hematology|June 5, 2003
Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trialsFrançois Guilhot, Martine Gardembas, Philippe Rousselot, et al.
Blood|February 24, 2007
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trialHagop Kantarjian, Ricardo Pasquini, Nelson Hamerschlak, et al.
Pageof 20